TRex Bio, Inc. (TRXB)

Price$15.24Cached quoteAs of 2026-10-21 23:25 UTC

AI: Fair-priced

Price checkTRXB trades approximately at its $14 IPO price, implying a roughly $381 million equity valuation. The stock appears fairly priced but highly speculative, with no established clinical efficacy for its lead drug.

The SEC confirms the exact registrant as TRex Bio, Inc., CIK 0002139097, with shares listed on the Nasdaq Global Select Market under TRXB. The IPO priced at $14.00 on October 8, 2026, and trading began October 9. StockAnalysis reports an October 26 closing price of $13.87 at 4:00 p.m. EDT, approximately 0.93% below the IPO price, with 54,974 shares traded. This is a dated historical quote, not an independently verified live executable quote. A separate market-data provider displays conflicting October 26 data, so the exact close should be treated with appropriate caution. Using 27,445,682 post-IPO shares outstanding, the indicative market capitalization is approximately $380.7 million. The IPO prospectus reports $90.9 million of cash, cash equivalents and marketable securities as of June 30, 2026 and estimates $103.5 million of net IPO proceeds, implying approximately $194.4 million of combined capital before subsequent operating spending. This is not a verified October 26 cash balance. On that simplified basis, approximately half the equity value is supported by historical cash plus IPO proceeds, with the remainder reflecting pipeline value and future expectations. The fair-priced verdict is a risk-adjusted qualitative judgment rather than a precise discounted-cash-flow valuation.

Big pictureTRexBio is an early clinical-stage immunology company, not a commercial biotechnology business. Its lead wholly owned asset, TRB-061, is in Phase 1a/b, with meaningful patient efficacy evidence still pending.

TRB-061 is a TNFR2 agonist designed to activate and expand tissue regulatory T cells. ClinicalTrials.gov identifier NCT06934252 corresponds to its randomized, double-blind, placebo-controlled Phase 1a/1b program. The Phase 1a portion tested healthy volunteers, while Phase 1b evaluates patients with moderate-to-severe atopic dermatitis. On August 26, 2026, the company reported results from 65 healthy volunteers showing dose-related pharmacokinetics, Treg activation and expansion, and no treatment-related serious adverse events or dose-limiting toxicities. These are preliminary human safety and pharmacodynamic observations, not demonstrated clinical efficacy in atopic dermatitis. Phase 1b includes exploratory clinical disease-activity assessments, with topline results expected in mid-2027. TRB-071, a CD30 agonist being developed for inflammatory diseases including inflammatory bowel disease, remains in IND-enabling preclinical development, with Phase 1 initiation targeted for the first half of 2027, subject to regulatory clearance. Preclinical animal observations and human genetic associations do not establish efficacy in patients. The company has no approved products and no product-sales revenue. Its valuation depends primarily on clinical development probabilities, financing capacity and future commercial potential rather than current earnings.

Business strengthPharmaceutical partnerships and substantial IPO funding provide credibility and runway, but research spending, dilution and a limited freely tradable share supply remain important risks.

The October 2026 final prospectus estimates $103.5 million in net IPO proceeds, excluding any subsequent underwriter-option exercise. Its stated spending plan combines IPO proceeds with existing capital: approximately $90 million for TRB-061 clinical development, including Phase 2 studies in atopic dermatitis and alopecia areata through topline data; approximately $10 million for TRB-071 development through a Phase 1 healthy-volunteer study; and the remainder for working capital and general corporate purposes. These are planned program allocations, not evidence that the amounts have already been spent. The company projects sufficient financing into the second half of 2029, conditional on its operating assumptions. Net losses increased from $17.7 million in the first half of 2025 to $29.3 million in the first half of 2026, highlighting rising development costs. The company reported an accumulated deficit of $123.6 million at June 30, 2026. It has raised approximately $220 million in historical equity financing and received $91 million through collaboration arrangements, including relationships with Eli Lilly and Janssen. These partnerships support scientific credibility but do not guarantee future approvals or revenue. The IPO issued 8,333,334 new shares, expanding the equity base to approximately 27.45 million shares before any additional underwriter shares. The underwriters also received an option for 1.25 million additional shares. Existing investors and other restricted holders may face contractual lockups, commonly around 180 days in biotechnology IPOs, but the exact applicable expiration dates and exceptions should be confirmed against the underwriting provisions rather than assumed. The initial IPO issuance represents approximately 30.4% of the stated post-offering shares, not a verified freely tradable float. A separate S-8 registration may increase future equity-compensation-related dilution. Additional financing before the projected runway ends remains poss

What could change the storyThe decisive milestone is mid-2027 Phase 1b patient data for TRB-061. Convincing clinical benefit could justify a premium valuation; weak efficacy, safety concerns or financing pressure could drive substantial downside.

The principal near-term catalyst is the planned mid-2027 topline readout in moderate-to-severe atopic dermatitis. Investors should distinguish Treg biomarker activation from clinically meaningful improvements in disease severity, itching and durability of response. Safety, tolerability, dose-response, pharmacodynamic findings in skin tissue and exploratory clinical activity will be important. A second milestone is the planned first-half-2027 Phase 1 initiation for TRB-071, which remains dependent on IND-enabling work and regulatory permission. Further progress in Lilly-partnered TRB-051, including anticipated Phase 2a development in lupus with cutaneous manifestations, could provide external validation, but that asset is partnered rather than wholly owned. Other possible catalysts include clinical trial enrollment updates, new collaboration economics, follow-on offerings, quarterly cash disclosures and changes in research spending. The principal bearish scenario is that mechanistic effects in healthy volunteers fail to translate into clinically competitive efficacy. The bullish scenario requires credible patient outcomes, acceptable safety, reproducible tissue-level biology and sufficient capital to advance development without excessive dilution. Until these outcomes are established, a fair-priced classification is more defensible than a strong undervaluation claim.

AI: News

October 13, 2026: TRexBio completes $116.7 million IPOTRexBio confirmed the closing of its IPO, selling 8,333,334 shares at $14.00 and establishing its Nasdaq Global Select Market listing under TRXB.

The company announced approximately $116.7 million in gross IPO proceeds, before underwriting discounts, commissions and offering expenses. All shares in the base offering were issued by TRexBio, rather than sold by existing shareholders. The final prospectus estimates approximately $103.5 million in net proceeds. This financing materially strengthens the company's development funding position but also increases shares outstanding. The additional 1.25 million-share underwriter option creates potential further dilution; the closing announcement alone does not establish whether that option was exercised. The transaction is the most important recent capital-markets development for TRXB and supports the company's stated runway into the second half of 2029.

August 26, 2026: TRB-061 demonstrates preliminary human proof of mechanismTRexBio reported positive Phase 1a safety and biomarker results in healthy volunteers, supporting continued Phase 1b development in atopic dermatitis.

The company reported results from 65 healthy adults enrolled in single- and multiple-ascending-dose cohorts. Treatment was generally well tolerated, with no treatment-related serious adverse events, dose-limiting toxicities or treatment-related discontinuations. Observed increases in Tregs and related immunoregulatory biomarkers provided preliminary evidence of target engagement. These findings supported selection of 24 mg and 50 mg doses for the Phase 1b patient study. The announcement reduces some early mechanistic uncertainty but does not demonstrate improvement in patient symptoms, long-term safety or commercial competitiveness. The next important evidence milestone remains the anticipated mid-2027 patient readout.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2025

2026

Financial statements

	2025	2024
Revenue	$0	$39.1M
Research & development	$29.8M	$35.0M
Operating income	−$37.8M	−$2.4M
Operating margin	N/A	−6.09%
EBITDA	−$37.6M	−$1.1M
EBITDA margin	N/A	−2.87%
Net income	−$34.8M	−$3.1M
Net profit margin	N/A	−8.04%
Diluted EPSper diluted share	-$33.20	-$8.92